The largest series to date to treat patients with STS with immune checkpoint therapy is the SARC028 study, a US multi-institutional phase II trial of the anti-PD1 mAb pembrolizumab that aimed to establish the efficacy and safety of the drug in two cohorts consisting of 40 patients each with soft tissue or bone sarcomas [16,17]. The gene discussed is PDCD1; the disease is telomere syndrome.